Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mohit Nanda (NPI 1750363396)

Field	Value
Entity Type	Individual
Organization	Mohit Nanda
Address	600 Peter Jefferson Pkwy
City	Charlottesville
State	VA
ZIP	22911
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	November 18, 2005

Payer Source	Total Paid
Medicare	$4.6M
Medicaid	$0

Key Findings

This provider is a retina specialist whose Medicare billing is overwhelmingly dominated by intravitreal drug therapy and retina-focused procedures: J0178 (aflibercept) accounts for $2.9M and 63.2% of Medicare revenue, J2777 (faricimab) contributes $802.1K and 17.6%, and 67028 (intravitreal injection) contributes $234.8K and 5.1%; the precomputed top three codes together account for 85.9% of the provider's total Medicare revenue, indicating a tightly concentrated service line.

The practice generates $4.6M in total Medicare revenue and has no Medicaid billing on file, so its commercial and Medicaid exposure is effectively zero in the available data; this makes the provider functionally single-payer within the public-program dataset and dependent on Medicare reimbursement trends.

On competitive standing for high-revenue therapeutics, the provider ranks #60 of 3204 nationally for J0178 (98th percentile; notably above typical national volume for this code), signaling a major national-level presence in aflibercept administration and above-typical procedural throughput for that drug. Similarly, 67028 ranks #123 of 4255 (97th percentile; notably above typical national volume for this code), reinforcing that intravitreal injection procedures are a significant, above-typical component of the practice.

Diagnostic and outpatient visit coding shows unusually high imaging and office-visit throughput: 92134 ranks #157 of 26868 (99th percentile; extreme outlier) and 92202 ranks #23 of 2327 (99th percentile; extreme outlier), while 99213 ranks #6231 of 457151 (99th percentile; extreme outlier). These rank/percentile labels imply the provider performs retinal OCT and extended ophthalmoscopy at volumes far above typical national peers, consistent with a high-volume retina referral practice.

The provider also bills newer intravitreal agents at appreciable scale: J2777 appears as $802.1K (17.6% of Medicare revenue) and ranks #333 of 2039 (84th percentile; typical, unremarkable volume), while J2781 produces $108K (2.4% of Medicare revenue) and ranks #139 of 490 (71th percentile; typical, unremarkable volume). This pattern suggests adoption of multiple intravitreal therapeutics with faricimab uptake notable but not as dominant as aflibercept.

Several ancillary procedural and diagnostic codes appear at high national percentiles but represent small shares of revenue, for example 92202 (2.4K claims, $11 avg paid/claim, 0.6% of Medicare revenue) and 92014 (1.1K claims, $88 avg paid/claim, 2.1% of Medicare revenue) — these support a workflow with substantial in-office imaging and follow-up visits that feed the high-volume injection practice. The combination of frequent imaging codes and injection procedures is consistent with a retina specialty practice model focused on medical retina management.

From a business-risk and contracting perspective, revenue concentration in a handful of high-cost injectable codes (J0178, J2777, 67028) means the provider’s Medicare revenue is sensitive to drug utilization patterns and reimbursement policy changes affecting those codes. Payers and network managers evaluating this profile should note the potential revenue and utilization impact if preferred-agent policies, prior-authorization rules, or site-of-care edits change for these high-share therapeutics.

The provider has an established tenure in the Medicare program, with NPI enumeration dated 2005-11-18 (~21 years ago), indicating long-standing participation and likely sustained referral relationships that align with the high procedural and diagnostic volumes observed in the claims mix.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

26 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	4,170	$690	$2.9M
J2777	Injection, faricimab‑svoa, 0.1 mg	27,660	$30	$802.1K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,760	$90	$234.8K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	3,840	$30	$111.5K
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	900	$120	$108K
J2778	Injection, ranibizumab, 0.1 mg	510	$190	$94.4K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	1,070	$90	$94.2K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,010	$70	$65.9K
J3490	Unclassified drugs	30	$1,790	$57.3K
92202	The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece…	2,410	$10	$26.6K

Showing 1–10 of 26

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 26 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Mohit Nanda — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

26 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	5	80	1,400	$690	$1.1M
J2777	13	60	13,200	$30	$517.1K
J2778	24	40	560	$180	$171.5K
67028	4	90	1,000	$90	$107.1K
J2781	5	20	560	$120	$86.6K
67042	21	20	20	$1,130	$33.8K
92014	83	870	170	$80	$32.8K
99214	8,301	12,890	140	$80	$21K
J3490	81	110	60	$280	$20.5K
J9035	43	60	170	$50	$19.9K

Showing 1–10 of 26

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mohit Nanda, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jacob Meyer	VA	Retina Specialist (Ophthalmology) Physician	$3.8M	$0
Ashley Blurton	VA	Nuclear Medicine Physician	$2.9M	$0
Yevgeniy Shildkrot	VA	Ophthalmology Physician	$1.5M	$0
Nader Moinfar	VA	Ophthalmology Physician	$1.4M	$0
Krishi Peddada	SC	Ophthalmology Physician	$1.3M	$0
Benjamin Harris	PA	Diagnostic Radiology Physician	$527.8K	$504.9K
Linda Armstrong	GA	Diagnostic Radiology Physician	$643.9K	$175.1K
Anjali Bal	PA	Internal Medicine Physician	$731.1K	$0
David Wood	CA	Diagnostic Radiology Physician	$641.3K	$2.7K
Todd Blodgett	PA	Diagnostic Radiology Physician	$380.1K	$254K

Nearby Providers

Other providers in the same ZIP code as Mohit Nanda, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Of Virginia Physicians Group	VA	Sports Medicine (Neuromusculoskeletal Medicine) Physician	$0	$84.6M
Compass Youth Services	VA	Community/Behavioral Health Agency	$0	$63.5M
Martha Jefferson Hospital	VA	General Acute Care Hospital	$0	$26.9M
Addiction Recovery Systems LLC	VA	Methadone Clinic	$127.5K	$11.5M
Children's Dentistry Of Charlottesville, P.C.	VA	Dentist	$0	$11M
Scott Chirichetti	VA	Pain Medicine Physician	$1.1M	$0
Stephen Vance	VA	MOHS-Micrographic Surgery Physician	$924.6K	$0
Vandana Nanda	VA	MOHS-Micrographic Surgery Physician	$912.2K	$0
Richard Messinger	VA	Pain Medicine Physician	$489.7K	$0
Rasheed Siddiqui	VA	Pain Medicine (Anesthesiology) Physician	$449.1K	$0

Mohit Nanda — Billing Profile & Reimbursement Data

Sign up for Mohit Nanda — Billing Profile & Reimbursement Data policy alerts

Mohit Nanda — Billing Profile & Reimbursement Data

Sign up for Mohit Nanda — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References